CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- PositionDebt-to-equity is 2.79×, higher than 95% of its Biotechnology peers (median 0.09×)
- FinancialsAltman Z-Score 0.15: distress zone
- Interpretations1 currently firing — 1
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
695.12MUSDvs all stocks (USD)
Revenue (TTM)
98.99MUSDvs all stocks (USD)
Profit Margin
-200.00%vs Biotechnology peers
Beta
0.8770xvs all stocks
52-Week Change
-60.78%vs all stocks
Market Capitalization
695.12MUSDvs all stocks (USD)
Enterprise Value
665.35MUSDvs all stocks (USD)
Forward P/E
-7.42xvs Biotechnology peers
Price to Sales (TTM)
7.02xvs Biotechnology peers
Price to Book (MRQ)
11.35xvs Biotechnology peers
Enterprise to Revenue
6.72xvs Biotechnology peers
Enterprise to EBITDA
-3.31xvs Biotechnology peers
Gross Margin
72.29%vs Biotechnology peers
Profit Margin
-200.00%vs Biotechnology peers
Operating Margin
-265.18%vs Biotechnology peers
Return on Assets (TTM)
-41.15%vs Biotechnology peers
Return on Equity (TTM)
-136.40%vs Biotechnology peers
Revenue (TTM)
98.99MUSDvs all stocks (USD)
Revenue per Share (TTM)
1.00USDUpdated Jul 19, 2026Quarterly Revenue Growth
184.50%vs Biotechnology peers
Gross Profit (TTM)
58.81MUSDvs all stocks (USD)
EBITDA (TTM)
-200.93MUSDvs all stocks (USD)
Net Income (TTM)
-197.98MUSDvs all stocks (USD)
Quarterly Earnings Growth (YoY)
184.47%vs Biotechnology peers
Operating Cash Flow (TTM)
-175.07MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
-98.28MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Jul 19, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
84.28MUSDFY2025 · Dec 31, 2025Cost of Goods Sold
20.42MUSDFY2025 · Dec 31, 2025Gross Profit
63.85MUSDFY2025 · Dec 31, 2025Operating Income
-179.45MUSDvs all stocks (USD)
Pre-tax Income
-171.38MUSDFY2025 · Dec 31, 2025Income Tax Expense
-80.00KUSDFY2025 · Dec 31, 2025Net Income
-171.30MUSDFY2025 · Dec 31, 2025EBIT
-168.78MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
-168.78MUSDFY2025 · Dec 31, 2025Research & Development
13.18MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
230.12MUSDFY2025 · Dec 31, 2025Non-operating Interest Income
10.67MUSDFY2025 · Dec 31, 2025Non-operating Interest Expense
2.60MUSDFY2025 · Dec 31, 2025Net Income from Continuing Operations
-171.30MUSDFY2025 · Dec 31, 2025Operating Cash Flow
-192.56MUSDFY2025 · Dec 31, 2025Free Cash Flow
-192.90MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
41.32MUSDFY2025 · Dec 31, 2025Interest Paid
2.45MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-171.30MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
-4.16MUSDFY2025 · Dec 31, 2025Stock-based Compensation
22.09MUSDFY2025 · Dec 31, 2025Other Non-cash Items
337.00KUSDFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-17.20MUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-22.34MUSDFY2025 · Dec 31, 2025Capital Expenditures
-339.00KUSDFY2025 · Dec 31, 2025Purchase of Investments
-242.03MUSDFY2025 · Dec 31, 2025Sale of Investments
307.00MUSDFY2025 · Dec 31, 2025Other Investing Activity
-7.86MUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
56.77MUSDFY2025 · Dec 31, 2025Long-term Debt Issuance
96.26MUSDFY2025 · Dec 31, 2025Other Financing Charges
2.66MUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
98.92MUSDFY2025 · Dec 31, 2025Shares Outstanding
99.30MSharesUpdated Jul 19, 2026Float Shares
48.43MSharesUpdated Jul 19, 2026Shares Short
21.73MSharesUpdated Jul 19, 2026Short Ratio
11.23daysvs all stocks
Short % of Shares Outstanding
31.58%vs all stocks
% Held by Insiders
16.21%vs all stocks
% Held by Institutions
91.68%vs all stocks
Total Cash (MRQ)
200.97MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
2.02USDUpdated Jul 19, 2026Total Debt (MRQ)
171.20MUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
2.79xvs Biotechnology peers
Current Ratio (MRQ)
4.94xvs Biotechnology peers
Book Value per Share (MRQ)
0.6170USDUpdated Jul 19, 2026Total Assets
327.65MUSDvs all stocks (USD)
Total Current Assets
284.90MUSDFY2025 · Dec 31, 2025Total Liabilities
213.39MUSDFY2025 · Dec 31, 2025Total Non-current Assets
42.76MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
174.25MUSDFY2025 · Dec 31, 2025Total Current Liabilities
39.15MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
41.32MUSDFY2025 · Dec 31, 2025Other Short-term Investments
203.67MUSDFY2025 · Dec 31, 2025Accounts Receivable
25.35MUSDFY2025 · Dec 31, 2025Inventory
8.37MUSDFY2025 · Dec 31, 2025Accounts Payable
5.72MUSDFY2025 · Dec 31, 2025Deferred Revenue
609.00KUSDFY2025 · Dec 31, 2025Other Current Liabilities
588.00KUSDFY2025 · Dec 31, 2025Long-term Debt
96.37MUSDFY2025 · Dec 31, 2025Other Non-current Liabilities
72.14MUSDFY2025 · Dec 31, 2025Common Stock (Book)
10.00KUSDFY2025 · Dec 31, 2025Retained Earnings
-294.60MUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
114.26MUSDvs all stocks (USD)
52-Week Low
6.66USDUpdated Jul 19, 202652-Week High
18.63USDUpdated Jul 19, 202652-Week Change
-60.78%vs all stocks
Beta
0.8770xvs all stocks
50-Day MA
8.60USDUpdated Jul 19, 2026200-Day MA
9.22USDUpdated Jul 19, 2026Avg 10-Day Volume
1.55MSharesUpdated Jul 19, 2026Avg 30-Day Volume
1.80MSharesUpdated Jul 19, 2026Diluted EPS (TTM)
-2.00USDUpdated Jul 19, 20261 interpretation currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsWhere is this company structurally exposed?
Ulcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated
It sits well below its peak, and the fall has been both deep and long.
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Debt-to-equity is 2.79×, higher than 95% of its Biotechnology peers (median 0.09×)Significant
Debt-to-equity: 2.79Industry median: 0.09Industry P95: 0.88Peers compared: 261
Structural Tensions
High gross margins eroded by operating costsNotable
Gross Margin: 0.72Profit Margin: -2.00
Significant cash reserves alongside high leverageNotable
Cash (USD): 200,968,992Total Debt (USD): 171,195,008Debt-to-Equity: 2.79
Looks liquid, but the distress score says otherwiseNotable
Current Ratio: 4.94Altman Z-Score: 0.15
Financial Health
Altman Z-Score 0.15: distress zoneCritical
Altman Z-Score: 0.15
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Companies that share the same coordination system — how they create, deliver, or capture value.
Hangzhou Minsheng Healthcare Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Revenio Group Oyj
Tier 1ProductionApproval-Gated PipelineRule
Shandong Keyuan Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Fuan Pharmaceutical Group Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Omeros Corporation
Tier 1ProductionApproval-Gated PipelineRuleRisk
Knight Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Beijing Science Sun Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Nanjing Vishee Medical Technology Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Obio Technology (Shanghai) Corp., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
BridgeBio Oncology Therapeutics, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
Super Micro Computer Inc
1 interpretationUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated
Xinjiang Zhundong Petroleum Technology Co., Ltd.
1 interpretationUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated
Hefei Urban Construction Group Co., Ltd.
1 interpretationUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated